Estimation of Usual Meat Intake Distribution Considering Meat Content in Processed Foods: Based on the KNHANES 2009 / 대한지역사회영양학회지

Objectives@#This study was conducted to estimate usual meat intake distribution, which may have been over/underestimated when estimations were made using only the third food codes of the Korea National Health and Nutrition Examination Survey (KNHANES). @*Methods@#For this purpose, 24-hour recall data from the 2009 Korea National Health and Nutrition Examination Survey, which conducted a partial 2-day survey of food intake, were used. The Multiple Source Method (MSM) was used to estimate the distribution of the usual intake of red and processed meats. @*Results@#The results of this study show that the mean intake of red meat was 45.07 g while that of processed meat was 4.33 g. These results are slightly higher than the consumption calculated using only tertiary food code, and the difference was statistically significant. Furthermore, characteristics of the estimated usual intake distribution were a smaller standard deviation, increased lower percentiles, and decreased upper percentiles compared to the 2- day mean intake distribution for both red and processed meats. The proportion of individuals not consuming red meat decreased substantially from approximately 37% to 0.7%. The proportion of consumption that exceeded 90 g, which is the upper limit of red meat intake recommended by the National Health Service (NHS), was only approximately 10% in the distribution of usual intake. @*Conclusions@#As the consumption of processed foods is expected to continuously increase, caution is needed regarding the processes used to calculate food (group) intake to avoid over/underestimation. Moreover, use of KNHANES data to calculate the proportion of the population at risk of insufficiency or excess intake of certain nutrients or food (group), based on one day intake that does not address within-individual variation, may lead to biased estimates.

Relationship of Left Ventricular Mass to Obesity in Normotensive Adults

BACKGROUND: Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor for cardiovascular morbidity and mortality. The combination of hypertension and obesity are well known to act as risk factors of left ventricular hypertrophy in a number of studies, but it is unclear whether obesity itself stimulates LVH independently. Therefore, we investigated the relationship of left ventricular mass to body size in normotensive adults. METHODS: A population sample of 240 normotensive (systolic BP < 140 mmHg and diastolic BP < 90 mmHg) adults (139 men and 101 women) was examined by echocardiography. We excluded adults with history of hypertension, thyroid diseases, diabetes mellitus and other cardiac diseases. Left ventricular mass normalized for height(2.7) was used in the analyses and left ventricular hypertrophy was defined as a value of 50 g/m(2.7) men or 47 g/m(2.7) in women. RESULTS: Left ventricular mass significantly and positively correlated with body mass index. On univariate correlation analysis after adjusting for age, the body mass index was associated with LV mass/height(2.7) (LVMI: Left Ventricular Mass Index) in males and body mass index, waist circumference, hip circumference and waist/hip circumference ratio were associated with LVMI in females. Left ventricular hypertrophy was more frequent in overweight (33.3%) and obese (39.4%) groups than in lean group (15.9%). CONCLUSION: Left ventricular mass was strongly related to obesity in normotensive adults, especially in females. Obesity may be an independent risk factor for left ventricular hypertrophy.

Relationship of Left Ventricular Mass to Obesity in Normotensive Adults

BACKGROUND: Left ventricular hypertrophy (LVH) has been shown to be an independent risk factor for cardiovascular morbidity and mortality. The combination of hypertension and obesity are well known to act as risk factors of left ventricular hypertrophy in a number of studies, but it is unclear whether obesity itself stimulates LVH independently. Therefore, we investigated the relationship of left ventricular mass to body size in normotensive adults. METHODS: A population sample of 240 normotensive (systolic BP < 140 mmHg and diastolic BP < 90 mmHg) adults (139 men and 101 women) was examined by echocardiography. We excluded adults with history of hypertension, thyroid diseases, diabetes mellitus and other cardiac diseases. Left ventricular mass normalized for height(2.7) was used in the analyses and left ventricular hypertrophy was defined as a value of 50 g/m(2.7) men or 47 g/m(2.7) in women. RESULTS: Left ventricular mass significantly and positively correlated with body mass index. On univariate correlation analysis after adjusting for age, the body mass index was associated with LV mass/height(2.7) (LVMI: Left Ventricular Mass Index) in males and body mass index, waist circumference, hip circumference and waist/hip circumference ratio were associated with LVMI in females. Left ventricular hypertrophy was more frequent in overweight (33.3%) and obese (39.4%) groups than in lean group (15.9%). CONCLUSION: Left ventricular mass was strongly related to obesity in normotensive adults, especially in females. Obesity may be an independent risk factor for left ventricular hypertrophy.

Risk Factors of Nephrocalcinosis in Very Low Birth Weight(VLBW) Infants / 소아과

PURPOSE: Nephrocalcinosis in very low birth weight(VLBW) infants were known to be caused by a longer duration of furosemide use. However, etiologies, pathogenesis and risk factors remain unclear. Therefore, we examined the incidence and risk factors of nephrocalcinosis in VLBW infants retrospectively. METHODS: Inborn babies of birth weights less than 1,500 gm were examined retrospectively. Data were reviewed on gestational age, birth weight, sex, 5-min Apgar score, oliguria on the first day, respiratory support, surfactant use, duration of nephrotoxic drug use(furosemide, gentamicin, amikin, vancomycin and amphotericin-B) and duration of total parenteral nutrition(TPN) use. Presence of bronchopulmonary dysplasia(BPD), bacterial sepsis, fungal sepsis, osteopenia and necrotizing enterocolitis(NEC) were also reviewed. Serum calcium, phosphorus, total protein, albumin, blood urea nitrogen (BUN) and creatinine at three to five weeks of age and at discharge were reviewed. RESULTS: A t-otal 141 infants were reviewed. 9.2%(13/141) of VLBW infants developed nephrocalcinosis. By univariate analysis, gestational age, birth weight, 5-min Apgar scores, duration of ventilation, duration of oxygen use, postnatal dexamethasone, phototherapy, nephrotoxic drugs(furosemide, amikin, vancomycin, and amphotericin) and TPN were significantly associated with nephrocalcinosis. Low phosphorus level at three to five weeks of age and high BUN levels at discharge were significantly associated with nephrocalcinosis. Presence of RDS, BPD, bacterial sepsis, fungal sepsis and NEC were also significantly associated with nephrocalcinosis. Multivariate analysis showed that the strongest predictors of nephrocalcinosis were duration of furosemide use and birth weight. CONCLUSION: Longer duration of furosemide use and lower birth weight are considered to be independent risk factors. Further more prospective and longterm follow up studies are needed.

The Effects of Patent Ductus Arteriosus on Pulmonary Function in Infants with Respiratory Distress Syndrome

PURPOSE: Patent ductus arteriosus (PDA) is a common problem in infants with respiratory distress syndrome (RDS). The reported effects of closure of ductus on pulmonary function are variable. The purpose of this study was to compare the respiratory indices between infants with RDS with and without PDA and in infants with PDA, between before and after closure of PDA. METHODS: The respiratory indices, settings of mechanical ventilation and arterial blood gas analysis were investigated in 31 infants who were admitted to Seoul National University Hospital NICU from June 1998 to May 1999 with a diagnosis of RDS. The respiratory parameters were compared between infants with and without PDA. In the infants with PDA, the parameters were compared before and after closure of PDA with administration of indomethacin. The diagnosis of a significant PDA was made by cardiovascular distress scoring of greater than 3 and echocardiographic confirmation of ductal shunt. RESULTS: Nineteen infants (61.3%) were diagnosed with PDA and 4 infants were excluded due to failure of closure. Infants with PDA showed lesser pre-surfactant PaCO2 (32.5+/-10.5 vs 43.5+/-8.5, P<0.05) and lesser total pulmonary compliance (0.65+/-0.20 vs 1.05+/-0.17, P<0.01), tidal volume (4.78+/-1.53 vs 7.19+/-2.02, P<0.05) and higher airway resistance (435+/-44 vs 301+/-49, P<0.01) at 12 hours after surfactant treatment than infants without PDA. In infants with PDA, oxygenation index (7.27+/-9.84 vs 3.29+/-6.21, P<0.05) and airway resistance(439+/-45 vs 291+/-93, P<0.05) were decreased and total pulmonary compliance (0.55+/-0.21 vs 1.35+/-0.48, P<0.05) were increased after closure of PDA. CONCLUSIONS: The pulmonary functions were poor in infants with PDA and closure of the ductus with indomethacin lead into a significant improvement in pulmonary function.

Predictors of Clinical Outcome in the Newborns of Persistent Pulmonary Hypertension Treated with Inhaled Nitric Oxide

PURPOSE: Inhaled nitric oxide (iNO) has been known to improve oxygenation in newborns with persistent pulmonary hypertension (PPHN). This study was performed to evaluate the predictors of clinical outcome in the newborn infants with PPHN treated with iNO. METHODS: Between September 1998 and August 2002, 23 newborn infants with PPHN treated with iNO were enrolled in this study. Reduction of oxygenation index (OI) and AaDO2 to 30% or more were defined as clinical response. Accoding to the response time within or after 12 hours, the clinical response was sub-categorized as early or delayed response, respectively. RESULTS: The mean gestational age and birth weight of 23 newborn infants were 36.7+/-4.4 weeks and 2,644+/-907 g. The mean baseline OI and AaDO2 were 22.20+/-13.63 and 477.16+/-127.96. There were ten non-responsders, eight early responsders and five delayed responders. Eleven neonates showed sustained response for 24 hours. The mean AaDO2, and PaO2 were decreased after 12 hours (P<0.05), while there was no difference in oxygenation index, arteral pH and PaCO2. The mortality rates of non-responders or not- sustained responders were higher than those of responders or sustained responders (P< 0.05). The birth weight of death group was lower than that of survival group and AaDO2, and OI at 12 hours after iNO therapy in survival group were lower than those in death group. CONCLUSION: Predictors of the clinical outcome of iNO therapy were clinical response patterns after iNO therapy, time taken until clinical response, duration of response and change of oxygenation at 12 hours after iNO therapy.

Predictors of Clinical Outcome in the Newborns of Persistent Pulmonary Hypertension Treated with Inhaled Nitric Oxide

PURPOSE: Inhaled nitric oxide (iNO) has been known to improve oxygenation in newborns with persistent pulmonary hypertension (PPHN). This study was performed to evaluate the predictors of clinical outcome in the newborn infants with PPHN treated with iNO. METHODS: Between September 1998 and August 2002, 23 newborn infants with PPHN treated with iNO were enrolled in this study. Reduction of oxygenation index (OI) and AaDO2 to 30% or more were defined as clinical response. Accoding to the response time within or after 12 hours, the clinical response was sub-categorized as early or delayed response, respectively. RESULTS: The mean gestational age and birth weight of 23 newborn infants were 36.7+/-4.4 weeks and 2,644+/-907 g. The mean baseline OI and AaDO2 were 22.20+/-13.63 and 477.16+/-127.96. There were ten non-responsders, eight early responsders and five delayed responders. Eleven neonates showed sustained response for 24 hours. The mean AaDO2, and PaO2 were decreased after 12 hours (P<0.05), while there was no difference in oxygenation index, arteral pH and PaCO2. The mortality rates of non-responders or not- sustained responders were higher than those of responders or sustained responders (P< 0.05). The birth weight of death group was lower than that of survival group and AaDO2, and OI at 12 hours after iNO therapy in survival group were lower than those in death group. CONCLUSION: Predictors of the clinical outcome of iNO therapy were clinical response patterns after iNO therapy, time taken until clinical response, duration of response and change of oxygenation at 12 hours after iNO therapy.